Plasmid DNA encoding gene products of viruses or other pathogens has recently been applied by intramuscular injection as a novel type of vaccine. It can induce cytotoxic T cell response in small animals and protect against challenge with influenza A viruses. Combinations with cytokines or DNA-encoding cytokines have been applied in order to increase the efficiency of protection. A DNA vaccine has been analyzed here against malignant melanoma encoding gp100/pmel17, a melanoma-associated antigen. A small animal model was used by injection of B16 melanoma cells to syngeneic C57Bl/6 mice. DNA vaccination before tumor cell challenge leads to about 50% reduction of tumor size. The cytokine gene coding for GM-CSF did not increase the efficiency but also led to tumor size reduction when applied alone.
Introduction
Plasmid DNA when applied to cell culture requires carriers for uptake such as calcium-phosphate to form miniprecipitates or liposomes or physical methods such as electroporation. Nevertheless uptake by cells is low amounting to only a few percent. This is partly due to the state of the cells; competence for uptake is possible for dividing cells only. In vivo plasmid DNA uptake is thought to be receptor-mediated, entering myotubular cells associated with the T-tubule system which are found only in skeletal and cardiac muscle. 1 Two candidates of 30 and 80 kDa have been found capable of binding plasmid DNA or oligodeoxynucleotides. Uptake is an active energy-dependent process. 1, 2 The original observation by Wolff et al 3 that DNA uptake by intramuscular injection was more efficient with naked DNA than in the presence of liposomes was a surprise. Plasmid DNA uptake has been compared in regenerating and mature muscle and is more efficient in the former. 2, 4 Once inside the cell, plasmid DNA persists and leads to dose-dependent and long-lived expression. 5 DNA vaccines mimick natural infections of pathogens by providing intracellular synthesis of foreign antigen. This leads to the stimulation of the immune system affording protection against viral challenge.
6-8 Protein expression leads to loading of major histocompatibility complex (MHC) class I molecules with peptides derived from expression of the plasmid DNAencoded neoantigen, permitting elicitation of cytotoxic T cell responses. The DNA vaccine resembles at this stage a liveattenuated vaccine which is, however, not allowed to replicate and therefore leads to reduced levels of viral antigen production compared to a real infection.
In contrast to a viral infection which in the case of HIV affects CD4
+ lymphocytes, intramuscular injection of DNA will target other cells. Whether myocytes are the ones to Correspondence: K Moelling; Fax: 41 16 34 49 67 induce cytotoxic lymphocyte CTL response is a matter of debate, since they express only low levels of MHC molecules and do not express the accessory costimulatory molecules such as B7.1 required for T cell activation (Figure 1a) . 9 Thus, neo-antigen expression in myocytes could theoretically even
Figure 1
Three models for the induction of the major histocompatibility complex (MHC) class-I-restricted cytotoxic lymphocyte (CTL) response by intramuscular DNA injection. (a) Direct presentation of the antigen (Ag) to the CTLs by the transduced myocyte cell. (b) Bone marrow-derived antigen presenting cells (APCs) may pick up locally released antigens, eg from dying myocytes, and present them through MHC class I molecules to CTLs. (c) Direct DNA uptake by the bone marrow-derived APCs infiltrating muscle tissue followed by intracellular processing and presentation of the antigen to CTLs. result in adverse events by promoting anergy or tolerance rather than priming a CTL response. Professional antigenpresenting cells (APCs) may take up the DNA directly ( Figure  1c ) and immediately carry it to distal sites of the body, eg to lymph nodes and spleen where the antigen is expressed and presented thereby converting naive CD8 + cells to cytotoxic T cells. Since it has been determined by many groups that plasmid DNA can stimulate responses governed not only by MHC class I, but also class II restricted T cell interaction, APCs can also take up peptides, eg from traumatized cells expressing the neo-antigens by macrophage engulfment (Figure 1b) . MHC class II intracellular processing is independent of intracellular protein synthesis but involves proteolytic processing of proteins taken up by the cell from the outside. This textbook view has been challenged recently, the trafficking routes of endogenously and exogenously derived peptides are not absolute. Endogenously processed peptides can also be presented by MHC class II molecules 10, 11 and some antigenpresenting cells can present exogenously derived peptides by MHC class I molecules, opposite to the normal routes of presentation.
Bone marrow-derived APCs were shown to dominate MHC class II-restricted CTL response over antigen presentation by myocytes. Indeed, sites of muscle tissue injected with DNA become infiltrated with inflammatory cells. 12 Bone marrowderived APCs within these inflammatory infiltrates may play an important role in the vaccine effect of naked DNA immunization. The APCs may travel to the draining lymph nodes where they could activate B and T cells.
The role of bone marrow-derived APCs, priming the immune response by naked DNA vaccine, has been analyzed by Ertl and colleagues who coinjected the gene for the rabies glycoprotein together with DNA encoding the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) and observed enhanced immunological responses. 13 GM-CSF may enhance the antigen-specific immune response by inducing differentiation of hemopoietic progenitor cells into professional APCs. In addition to macrophages, GM-CSF has been shown to induce the differentiation and maintenance of dendritic cells (DCs). DCs are two to three logs more potent in activating naive T cells in vitro than macrophages, suggesting that they are the important APCs in initiating immune responses in vivo. 12, 14 We have used a DNA vaccination approach against malignant melanoma by expressing a melanoma-associated antigen pmel17/gp100 from the plasmid DNA.
15 gp100 is one of several melanoma-associated antigens and was considered as a model gene to evaluate the DNA vaccination procedure against a tumor. This has not been analyzed so far. In order to increase the efficiency of the DNA vaccine we combined it with DNA encoding GM-CSF.
Materials and methods

Vector construction and plasmid DNA preparation
cDNA coding for gp100/pmel17 and murine GM-CSF were inserted downstream of the immediate-early enhancer/ promoter region from cytomegalovirus (CMV). The plasmid also carries the intron A sequence of CMV, a bovine growth hormone terminator sequence and a Kanamycin resistance gene in a pUC18 backbone. Large scale preparations of plasmid DNA were carried out with endotoxin-free buffers according to the protocol of Qiagen (Hilden, Germany). The quality of DNA preparations was verified by gel-electrophoresis. Only closed-circular DNA was injected into animals. Expression of gp100/pmell17 and GM-CSF was tested by transient transfection experiments in 293 cells. In case of the gp100/pmel17 construct which contained a N-terminal FLAG epitope immunofluorescence was performed using the monoclonal FLAG antibody M2 (Kodak, New Haven, CT, USA). To determine GM-CSF levels in vitro culture medium was collected from transfected cells to different time-points and analyzed using a commercial ELISA kit. All methods have been described previously. 15 
Animal experimentation
Groups of 10 C57B1/6 mice were injected twice with 50 g plasmid DNA at day 35 and 14 prior to tumor cell challenge. As controls served mice injected with the same plasmid without insert and uninjected animals, respectively. The latter one was chosen to evaluate a possible background immune response to the plasmid DNA by itself. Since such a response could not be seen only the tumor growth curve of mice immunized with mock vector DNA is shown. Tumor cell challenge was carried out by subcutaneous injection of 1 × 10 6 syngeneic B16-F0 mouse melanoma cells by the subcutaneous route. Beginning 5 days after tumor challenge, tumor volumes present were determined by measuring the largest diameter (d1) and the perpendicular diameter thereof (d2). Tumor volumes were calculated according to the formula d1 × (d2) 2 × 0.5.
Results and discussion
We have analyzed the effect of plasmid DNA vaccination against malignant melanoma by expressing the gp100/pmel17. 15, 16 Animals were vaccinated with 50 g of DNA twice, 5 and 2 weeks before the tumor challenge with 1 × 10 6 B16-F0 melanoma tumor cells in syngeneic C57B1/6 mice occurred. Tumor formation was determined by caliper for up to 30 days (Figure 2a) . The result of this experiment is shown in Figure 2b . Tumor volumes are reduced by about 50%, however the tumor incidence was not affected. In order to improve the treatment and to offer the possibility for an enhancement of the subsequent response to the DNA-encoded antigen we constructed a DNA plasmid expressing murine GM-CSF and a plasmid containing both constructs which were connected by an internal ribosomal entry site (IRES), respectively. Thus, the two transgenes were driven by the same promoter allowing a simultaneous expression in each transfected target cell. Protein expression was verified in vitro after transient transfection experiments with 293 cells. The amount of GM-CSF secreted into the supernatant was in the range of 100 g/ml per 24 h. The FLAG tagged gp100/pmel17 expressing cells were visualized in immunofluorescence studies using the mouse FLAG antibody M2 and a second antimouse TRITC-conjugated antibody: up to 95% of cells were positive for gp100 (data not shown). Co-injection of the GM-CSF DNA with the gp100/pmel17-coding plasmid was carried out by mixing 50 g of each DNA prior to injection. In parallel 100 g of the gp100/pmel17-IRES-GM-CSF DNA was injected intramuscularly. Although a different distributed uptake and expression of the melanoma-associated antigen and the cytokine had to be expected in the approach with the two mixed DNAs no better vaccination effect could DNA vaccination against malignant melanoma. (a) Schematic drawing depicting the DNA vaccination scheme. Mice were vaccinated twice by the intramuscular route with 50 g of plasmid DNA 35 and 14 days prior to tumor challenge. Tumor cell injection was carried out by the subcutaneous route. (b) Groups of 10 C57BI/6 mice were vaccinated with 50 g of the control plasmid () or plasmids directing the expression of gp100 (v) or GM-CSF (̅). One group received a mixture of 50 g gp100 and 50 g GM-CSF-coding plasmid DNA per immunization (ć). Two weeks following the booster the animals were challenged with 1 × 10 6 B16-F0 melanoma cells. The standard deviation is indicated by error bars. Immunization with gp100/pmel17-or GM-CSF plasmid DNA or with a mixture of both of them decreased the tumor growth following tumor challenge (P р 0.01 for GM-CSF, P р 0.05 for gp100/pmel17 and the mixture of both plasmid DNAs; median test under consideration of a Bonferroni correction).
be achieved with the construct in which both coding genes were combined with an IRES-sequence (data therefore not shown). As control GM-CSF-expressing DNA was injected individually. The result shown in Figure 2b demonstrates that application of a combination had no synergistic effect. Interestingly, GM-CSF encoding plasmid DNA exhibited the highest significance in tumor reduction (P р 0.01 in comparison to P р 0.05). Taken together, the tumors of DNA vaccinated mice appeared delayed and therefore it resulted in a prolonged survival.
The result is of specific interest since it demonstrates that plasmid DNA is not only applicable for immunization but also as gene medicine, however, at this stage with limited success. Also other cytokines can be expressed this way, eg IL-12 which is presently under investigation and shows efficiency as anti-metastatic treatment. Some dosage effects have even been achieved by changing the amount of DNA injected (unpublished observation).
In the literature only a few reports on DNA vaccine against cancer have been discussed. The first DNA vaccine against cancer was developed against a B cell lymphoma in which one set of variable (V) immumoglobulin genes consists of one idiotype that can be controlled by anti-idiotypic antibodies. DNA encoding this idiotype could present a simple way of raising anti-idiotypic antibodies. Some promising results have been observed in clinical trials. 17 Another antigen under investigation is the carcinoembryonic antigen CEA. Recombinant vaccinia vaccines expressing CEA stimulated both cellular and humoral responses and protected against challenge with syngeneic CEA-expressing colon carcinoma lines in mice. 18 This CEA-encoding plasmid was developed and is being investigated for treatment of human colon-, breast-and non-small cell lung cancers expressing CEA. Low amounts of the 180 kDa CEA glycoprotein are expressed in normal tissue which supports the view that humans show tolerance to CEA. CEA-DNA has been tested in preclinical studies in a murine model with syngeneic colon adenocarcinoma. DNA vaccination was carried out with the human CEA which shows 50 to 60% homology to the murine one. Induction of humoral and cellular immunity was observed as well as immunoprotection against challenge with 2 × 10 5 colon tumor cells. The effects of vaccination with recombinant vaccinia viral CEA and CEA-DNA were similar. A phase I/II clinical trial was approved in Autumn 1996 for the University of Alabama. The plasmid encodes the human CEA and the HBV surface antigen (HBsAg), 18 each of them under the control of the CMV promoter. The HBsAg gene within the clinically applied plasmid will allow verification of the immunizing DNA, the vaccination schedule and will be efficacy-independent of the patient's immune response to CEA. A draw-back of the preclinical data for this protocol is the fact that the human CEA is not a self-antigen in mice as it is in humans. A mouse-CEA has not been tested.
For tumors that express normal tissue antigens such as CEA or PSA breaking self-tolerance may be necessary. This may be aided by coexpression of coactivators to stimulate immune responses.
Injection of plasmid DNA encoding cytokines has been shown to regulate humoral and cellular immune responses to exogenous antigens. 19 DNA immunization against B cell lymphoma was performed without and with DNA encoding GM-CSF. Addition of GM-CSF to the construct resulted in earlier antibody responses and yielded a higher proportion of responsive mice, 97% of immunized mice exhibited specific antibody responses compared to 62% without GM-CSF and the survival rate was also higher. 18 Similar findings were made with GM-CSF expressed on separate plasmids. 13, 20 In the results reported here GM-CSF did not increase the antitumor efficiency of gp100-encoding DNA. Surprisingly, GM-CSF by itself was more effective in reducing tumor formation than gp100. This suggests that cytokine genes may result in expression of biologically effective amounts when injected intramuscularly. We observed similar effects with IL-12 DNA.
One could envisage an application of a DNA therapy with genes coding for insulin, anti-inflammatory cytokines, neurotropic factors etc. Whenever very low amounts of proteins such as hormones, growth factors or cytokines are sufficient to generate a biological effect, DNA may have its potential. It may not be efficient enough for gene replacement of defective genes which require larger amounts of proteins such as hypercholesterolemia or cystic fibrosis.
